Multi-laboratory measurement of ibutilide inhibition of recombinant hERG1a
Cell-based study · CHO cells expressing hERG1a (Lab 1) and HEK293 cells expressing hERG1a (Labs 2, 4 and 5); Lab 3 did not participate in Phase 2. [1]
Four laboratories measured ibutilide hERG inhibition. Concentration-corrected potency estimates differed across laboratories; the anonymized lab labels cannot be assigned to named drug sources. These are electrophysiological endpoints, not treatment doses or evidence of clinical efficacy.
| Endpoint | Reported result | Reference |
|---|---|---|
| hERG1a outward ramp current inhibition, anonymized Lab 1 | pIC50 7.9277; reported 95% CI column: 0.0347 | [1] |
| hERG1a outward ramp current inhibition, anonymized Lab 2 | pIC50 8.4643; reported 95% CI column: 0.157 | [1] |
| hERG1a outward ramp current inhibition, anonymized Lab 4 | pIC50 8.2481; reported 95% CI column: 0.0742 | [1] |
| hERG1a outward ramp current inhibition, anonymized Lab 5 | pIC50 7.9580; reported 95% CI column: 0.138 | [1] |
Literature-Reported Treatment Conditions
- Method
- Drug application during manual whole-cell patch clamp at near-physiological temperature: Lab 1, 36 ± 1 °C; Lab 2, 35–38 °C; Lab 4, 36 ± 1 °C; Lab 5, 37 ± 2 °C. Step-ramp stimulus at 0.2 Hz.
- Co-treatment
- No therapeutic drug combination. E-4031 served as an endpoint current-isolation control (1 µM for the four Phase 2 laboratories).
- Reported limits
- Ibutilide-specific concentration series, exposure durations, vehicle composition and cell counts were not extracted from raw electrophysiology reports. General request to test at least four concentrations is not an ibutilide-specific verified dose series.
Methods and source locations
Compound reported in the paper: Ibutilide; Compound label in the paper: Ibutilide; source table includes AdooQ Bioscience A11750 and Tocris 3908
Supports ibutilide hERG inhibition in this recombinant cellular assay, including a documented A11750 source contribution. Numerical values belong to anonymized laboratories and are not A11750-specific product potency specifications.
Methods Sec3–6 and Sec8–10; Results Sec17 and Figure 4; Supplementary Material 1 Tables 1, 2, 4 and 6 (Ibutilide rows)
hERG1a outward ramp current inhibition, anonymized Lab 1: Manual whole-cell patch clamp; variable-slope Hill fit using concentration-corrected data. CI is retained as the scalar printed in the table; it is not SD, SEM or sample size. — Supplementary Material 1, Supplemental Table 4, Ibutilide row 22, B22:C22; Methods Sec10 (Estimation of drug potencies)
hERG1a outward ramp current inhibition, anonymized Lab 2: Manual whole-cell patch clamp; variable-slope Hill fit using concentration-corrected data. CI is retained as the scalar printed in the table; it is not SD, SEM or sample size. — Supplementary Material 1, Supplemental Table 4, Ibutilide row 22, D22:E22; Methods Sec10 (Estimation of drug potencies)
hERG1a outward ramp current inhibition, anonymized Lab 4: Manual whole-cell patch clamp; variable-slope Hill fit using concentration-corrected data. CI is retained as the scalar printed in the table; it is not SD, SEM or sample size. — Supplementary Material 1, Supplemental Table 4, Ibutilide row 22, H22:I22; Methods Sec10 (Estimation of drug potencies)
hERG1a outward ramp current inhibition, anonymized Lab 5: Manual whole-cell patch clamp; variable-slope Hill fit using concentration-corrected data. CI is retained as the scalar printed in the table; it is not SD, SEM or sample size. — Supplementary Material 1, Supplemental Table 4, Ibutilide row 22, J22:K22; Methods Sec10 (Estimation of drug potencies)